Limits...
German cancer statistics 2004.

Haberland J, Bertz J, Wolf U, Ziese T, Kurth BM - BMC Cancer (2010)

Bottom Line: Traditionally, the RKI periodically estimates the number of new cancer cases in Germany on the basis of the available data from the regional cancer registries in which registration is complete; this figure, in turn, forms the basis for further important indicators.In women, breast cancer remains the most common cancer with an estimated 57,000 new cases every year, also followed by colorectal cancer.In addition, the RKI made cancer-prevalence estimates and calculated current morbidity and mortality risks at the federal level for the first time.

View Article: PubMed Central - HTML - PubMed

Affiliation: Robert Koch Institute, Department of Epidemiology and Health Reporting, Papestrasse 62-66, 12101 Berlin, Germany. haberlandj@rki.de

ABSTRACT

Background: For years the Robert Koch Institute (RKI) has been annually pooling and reviewing the data from the German population-based cancer registries and evaluating them together with the cause-of-death statistics provided by the statistical offices. Traditionally, the RKI periodically estimates the number of new cancer cases in Germany on the basis of the available data from the regional cancer registries in which registration is complete; this figure, in turn, forms the basis for further important indicators.

Methods: This article gives a brief overview of current indicators - such as incidence, prevalence, mortality, survival rates - on the most common types of cancer, as well as important ratios on the risks of developing and dying of cancer in Germany.

Results: According to the latest estimate, there were a total of 436,500 new cancer cases in Germany in 2004. The most common cancer in men is prostate cancer with over 58,000 new cases per annum, followed by colorectal and lung cancer. In women, breast cancer remains the most common cancer with an estimated 57,000 new cases every year, also followed by colorectal cancer. These and further findings on selected cancer sites can be found in the current brochure on "Cancer in Germany", which is regularly published by the RKI together with the Association of Population-based Cancer Registries in Germany (GEKID). In addition, the RKI made cancer-prevalence estimates and calculated current morbidity and mortality risks at the federal level for the first time. According to these figures, the 5-year partial prevalence - i.e. the total number of cancer patients diagnosed over the past five years who are currently still living - exceeds 600,000 in men; the figure is about the same among women. Here, too, the most common cancers are prostate cancer in men and breast cancer in women. The lifetime risk of developing cancer, which is more related to the individual, is estimated to be higher among men (48.5%) than among women (40.3%). In roughly rounded figures, therefore, about every second person in Germany develops cancer in the course of their lives. One in four men and one in five women die of cancer.

Conclusions: In recent years, population-based cancer registration in Germany has come significantly closer to the aim of the complete, nationwide coverage of cancer. The continuous improvements in the data situation help describe cancer development in Germany.

Show MeSH

Related in: MedlinePlus

Cumulated relative survival rates for selected cancer sites.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2837012&req=5

Figure 4: Cumulated relative survival rates for selected cancer sites.

Mentions: Figure 4 shows the development of the cumulative relative survival rates of people suffering from the cancers covered in this article over the first 10 years after diagnosis. Of these sites, the survival expectations of male patients diagnosed with prostate cancer are the most favourable, followed by female patients with breast cancer. The survival expectations of patients with lung cancer are still very unfavourable for both sexes [19]. A comparison of the current 5-year relative survival rates calculated here using period analysis (period window 2000-2004) with the results of a traditional cohort analysis (diagnosis period 1993-1997) shows particularly striking improvements in the case of prostate cancer within this short time span [1].


German cancer statistics 2004.

Haberland J, Bertz J, Wolf U, Ziese T, Kurth BM - BMC Cancer (2010)

Cumulated relative survival rates for selected cancer sites.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2837012&req=5

Figure 4: Cumulated relative survival rates for selected cancer sites.
Mentions: Figure 4 shows the development of the cumulative relative survival rates of people suffering from the cancers covered in this article over the first 10 years after diagnosis. Of these sites, the survival expectations of male patients diagnosed with prostate cancer are the most favourable, followed by female patients with breast cancer. The survival expectations of patients with lung cancer are still very unfavourable for both sexes [19]. A comparison of the current 5-year relative survival rates calculated here using period analysis (period window 2000-2004) with the results of a traditional cohort analysis (diagnosis period 1993-1997) shows particularly striking improvements in the case of prostate cancer within this short time span [1].

Bottom Line: Traditionally, the RKI periodically estimates the number of new cancer cases in Germany on the basis of the available data from the regional cancer registries in which registration is complete; this figure, in turn, forms the basis for further important indicators.In women, breast cancer remains the most common cancer with an estimated 57,000 new cases every year, also followed by colorectal cancer.In addition, the RKI made cancer-prevalence estimates and calculated current morbidity and mortality risks at the federal level for the first time.

View Article: PubMed Central - HTML - PubMed

Affiliation: Robert Koch Institute, Department of Epidemiology and Health Reporting, Papestrasse 62-66, 12101 Berlin, Germany. haberlandj@rki.de

ABSTRACT

Background: For years the Robert Koch Institute (RKI) has been annually pooling and reviewing the data from the German population-based cancer registries and evaluating them together with the cause-of-death statistics provided by the statistical offices. Traditionally, the RKI periodically estimates the number of new cancer cases in Germany on the basis of the available data from the regional cancer registries in which registration is complete; this figure, in turn, forms the basis for further important indicators.

Methods: This article gives a brief overview of current indicators - such as incidence, prevalence, mortality, survival rates - on the most common types of cancer, as well as important ratios on the risks of developing and dying of cancer in Germany.

Results: According to the latest estimate, there were a total of 436,500 new cancer cases in Germany in 2004. The most common cancer in men is prostate cancer with over 58,000 new cases per annum, followed by colorectal and lung cancer. In women, breast cancer remains the most common cancer with an estimated 57,000 new cases every year, also followed by colorectal cancer. These and further findings on selected cancer sites can be found in the current brochure on "Cancer in Germany", which is regularly published by the RKI together with the Association of Population-based Cancer Registries in Germany (GEKID). In addition, the RKI made cancer-prevalence estimates and calculated current morbidity and mortality risks at the federal level for the first time. According to these figures, the 5-year partial prevalence - i.e. the total number of cancer patients diagnosed over the past five years who are currently still living - exceeds 600,000 in men; the figure is about the same among women. Here, too, the most common cancers are prostate cancer in men and breast cancer in women. The lifetime risk of developing cancer, which is more related to the individual, is estimated to be higher among men (48.5%) than among women (40.3%). In roughly rounded figures, therefore, about every second person in Germany develops cancer in the course of their lives. One in four men and one in five women die of cancer.

Conclusions: In recent years, population-based cancer registration in Germany has come significantly closer to the aim of the complete, nationwide coverage of cancer. The continuous improvements in the data situation help describe cancer development in Germany.

Show MeSH
Related in: MedlinePlus